Communiqués Zymeworks Inc.

Actions

ZYME

US98985Y1082

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
25,79 ^USD	+2,10%		+2,54%	-2,05%

08/10	Viatris va acquérir Pacira BioSciences pour 1,65 milliard de dollars	MT
28/09	Transcript : Zymeworks Inc., Theravance Biopharma, Inc. - M&A Call

Communiqués

28/09	Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition	GL
28/09	Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition	AQ
23/09	Zymeworks Completes Acquisition of Theravance Biopharma	GL
25/08	U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma	GL
11/08	Zymeworks Announces Participation in Upcoming Investor Conferences	GL
07/08	Zymeworks : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results	GL
06/08	Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results	AQ
16/07	Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026	GL
29/06	Zymeworks to Acquire Theravance Biopharma, Inc.	GL
18/06	Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery	AQ
15/06	Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026	GL
14/05	Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock	GL
14/05	Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock	AQ
13/05	Zymeworks Announces Participation in Upcoming Investor Conferences	GL
08/05	Zymeworks : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
08/05	Zymeworks : ZYME Q1 2026 Earnings Presentation May 7 2026	PU
07/05	Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results	GL
07/05	Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results	AQ
21/04	Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026	GL
17/04	Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform	GL
16/04	Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026	GL
09/04	Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth	GL
01/04	Zymeworks Appoints Kristin Stafford as Chief Financial Officer	GL
30/03	Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate	GL